Head-To-Head Comparison: Black Diamond Therapeutics (NASDAQ:BDTX) & Xenetic Biosciences (NASDAQ:XBIO)

Xenetic Biosciences (NASDAQ:XBIO) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Profitability

This table compares Xenetic Biosciences and Black Diamond Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

Earnings and Valuation

This table compares Xenetic Biosciences and Black Diamond Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98 million	1.64	-$2.68 million	($1.16)	-1.84
Black Diamond Therapeutics	$70.00 million	1.50	$22.37 million	($0.75)	-2.44

Black Diamond Therapeutics has higher revenue and earnings than Xenetic Biosciences. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Xenetic Biosciences and Black Diamond Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1	0	0	0	1.00
Black Diamond Therapeutics	1	2	8	0	2.64

Black Diamond Therapeutics has a consensus price target of $10.25, indicating a potential upside of 460.11%. Given Black Diamond Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Xenetic Biosciences.

Institutional & Insider Ownership

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Xenetic Biosciences has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 3.32, suggesting that its stock price is 232% more volatile than the S&P 500.

Summary

Black Diamond Therapeutics beats Xenetic Biosciences on 12 of the 14 factors compared between the two stocks.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.